Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lactobacillus reuteri (BioGaia AB)
- Development stage
- Preclinical
- Lead developer
- BioGaia
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
- Administration
- Buccal, Oral
01
Overview
Lactobacillus reuteri (often misspelled as L. retueri) is a probiotic bacterium. A specific formulation containing two strains of L. reuteri, DSM 17938 and ATCC PTA 5289, has been developed and studied by the University of Copenhagen (Department of Odontology, Faculty of Health and Medical Sciences) and BioGaia. Administered as a daily oral lozenge or tablet, this probiotic targets the oral microbiome to inhibit cariogenic bacteria, such as Streptococcus mutans, which contribute to enamel demineralization and dental caries. Clinical trials, including those using quantitative light-induced fluorescence (QLF) to measure enamel mineral loss, have investigated its efficacy in children and adolescents with white spot lesions. The formulation is commercially marketed under the brand name BioGaia Prodentis.
- Brand names
- BioGaia ProdentisProdentis
- Other names
- L. retueriL. reuteriLactobacillus reuteriLactobacillus reuteri ATCC PTA 5289Lactobacillus reuteri DSM 17938Limosilactobacillus reuteri
02
Targets
LDH (L-lactate dehydrogenase A chain)LuxS (S-ribosylhomocysteine lyase)
Beyond the preview
Go deeper on lactobacillus reuteri (BioGaia AB).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lactobacillus reuteri (BioGaia AB).